Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox

References

• . Gregg EW, Cheng YJ, Saydah S, . Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care. 2012;35(6):1252–1257
   PubMed Web of Science ®Google Scholar
• . Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–2581
   PubMed Web of Science ®Google Scholar
• . Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131–1137
   PubMed Web of Science ®Google Scholar
• . Stern MP. Diabetes and CV disease. The “common soil” hypothesis. Diabetes. 1995;44(4):369–374
   PubMed Web of Science ®Google Scholar
• . McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol. 1990;131(3):443–453
   PubMed Web of Science ®Google Scholar
• . Preis SR, Pencina MJ, Mann DM, D'Agostino RB Sr, Savage PJ, Fox CS. Early-adulthood cardiovascular disease risk factor profiles among individuals with and without diabetes in the Framingham Heart Study. Diabetes Care. 2013;36(6):1590–1596
   PubMed Web of Science ®Google Scholar
• . Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129–1134
   PubMed Web of Science ®Google Scholar
• . Aguilar D, Solomon SD, Køber L, . Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004;110(12):1572–1578
   PubMed Web of Science ®Google Scholar
• . Smith NL, Barzilay JI, Kronmal R, Lumley T, Enquobahrie D, Psaty BM. New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care. 2006;29(9):2012–2017
   PubMed Web of Science ®Google Scholar
• . Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
   PubMed Web of Science ®Google Scholar
• . National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421
   PubMed Web of Science ®Google Scholar
• . , Emerging Risk Factors CollaborationSarwar N, Gao P, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [Erratum in Lancet. 2010;376(9745): 958]. Lancet. 2010;375(9733):2215–2222
   PubMed Web of Science ®Google Scholar
• . Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164(13):1422–1426
   PubMedGoogle Scholar
• . Spencer EA, Pirie KL, Stevens RJ, ; Million Women Study Collaborators. Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur J Epidemiol. 2008;23(12):793–799
   PubMed Web of Science ®Google Scholar
• . Gore MO, Patel MJ, Kosiborod M, ; National Registry of Myocardial Infarction Investigators. Diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006: data from the National Registry of Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2012;5(6):791–797
   PubMed Web of Science ®Google Scholar
• . Kamalesh M, Subramanian U, Ariana A, Sawada S, Tierney W. Similar decline in post-myocardial infarction mortality among subjects with and without diabetes. Am J Med Sci. 2005;329(5):228–233
   PubMed Web of Science ®Google Scholar
• . Eriksson M, Carlberg B, Eliasson M. The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study. Cerebrovasc Dis. 2012;34(2):153–160
   PubMed Web of Science ®Google Scholar
• . Booth GL, Kapral MK, Fung K, Tu JV. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care. 2006;29(1):32–37
   PubMed Web of Science ®Google Scholar
• . Taylor KS, Heneghan CJ, Farmer AJ. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36(8):2366–2371
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, ; American Diabetes Association; European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [Erratum in Diabetes Care. 2013;36(2): 490]. Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Reusch JE, Wang CC. Cardiovascular disease in diabetes: where does glucose fit in? J Clin Endocrinol Metab. 2011;96(8):2367–2376
   PubMed Web of Science ®Google Scholar
• . Selvin E, Marinopoulos S, Berkenblit G, . Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431
   PubMed Web of Science ®Google Scholar
• . Gao L, Matthews FE, Sargeant LA, Brayne C; MRC CFAS. An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health. 2008;8:54
   PubMed Web of Science ®Google Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [Erratum in Lancet. 1998;352(9139): 1558]. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [Erratum in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . ; Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein HC, Miller ME, Byington RP, Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes [Erratum in N Engl J Med. 2009;361(10):1024–1025, and N Engl J Med. 2009;361(10):1028]. New Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Ray KK, Seshasai SR, Wijesuriya S, . Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772
   PubMed Web of Science ®Google Scholar
• . Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19(9):604–612
   PubMed Web of Science ®Google Scholar
• . ; Control GroupTurnbull FM, Abraira C, Anderson RJ, Intensive glucose control and macrovascular outcomes in type 2 diabetes [Erratum in Diabetologia. 2009;52(1):2470]. Diabetologia. 2009;52(11):2288–2298
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO, ; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [Erratum in Diabetes Care. 2009;32(4):754]. Diabetes Care. 2009;32(1):187–192
   PubMed Web of Science ®Google Scholar
• . Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533
   PubMed Web of Science ®Google Scholar
• . ; ORIGIN Trial InvestigatorsGerstein HC, Bosch J, Dagenais GR, Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328
   PubMed Web of Science ®Google Scholar
• . Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, . Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169
   PubMed Web of Science ®Google Scholar
• . Ussher JR, Sutendra G, Jaswal JS. The impact of current and novel anti-diabetic therapies on cardiovascular risk. Future Cardiol. 2012;8(6):895–912
   PubMedGoogle Scholar
• . Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126–135
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [Erratum in N Engl J Med. 2007;357(1):100]. N Engl J Med. 2007;356(24):2457–2471
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586
   PubMed Web of Science ®Google Scholar
• . Roche halts investigation of aleglitazar following regular safety review of phase III trial [media release]. Basel, Switzerland: Roche; July 10, 2013. http://www.roche.com/media/media_releases/medcor-2013-07-10.htm. Accessed May 1, 2014
   Google Scholar
• . Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191–1201
   PubMed Web of Science ®Google Scholar
• . FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. Silver Spring, MD: US Food And Drug Administration; November 25, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm. Accessed May 1, 2014
   Google Scholar
• . Mahaffey KW, Hafley G, Dickerson S, . Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166(2):240–249.e1
   PubMed Web of Science ®Google Scholar
• . Dormandy JA, Charbonnel B, Eckland DJ, ; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Abrahamson MJ, Barzilay JI, ; American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327–336
   PubMed Web of Science ®Google Scholar
• . Pioglitazone (Actos) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2013. http://www.takeda.us/products/. Accessed May 1, 2014
   Google Scholar
• . US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Published December 2008. Accessed May 1, 2014
   Google Scholar
• . European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Published May 14, 2012. Accessed May 1, 2014
   Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;379( Suppl 1):S14–S80
   Google Scholar
• . Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther. 2013;27(1):5–16
   PubMed Web of Science ®Google Scholar
• . Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6
   PubMed Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group [Erratum in Diabetes. 1996;45(11):1655]. Diabetes. 1995;44(11):1249–1258
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Marx N, Kahn SE, . Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10(4):289–301
   PubMed Web of Science ®Google Scholar
• . Schramm TK, Gislason GH, Vaag A, . Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study [Erratum in Eur Heart J. 2012;33(10):1183]. Eur Heart J. 2011;32(15):1900–1908
   PubMed Web of Science ®Google Scholar
• . Tzoulaki I, Molokhia M, Curcin V, . Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• . Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25(12):2244–2248
   PubMed Web of Science ®Google Scholar
• . Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930–936
   PubMed Web of Science ®Google Scholar
• . Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938–953
   PubMed Web of Science ®Google Scholar
• . Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013;30(10):1160–1171
   PubMed Web of Science ®Google Scholar
• . Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care. 2008;31(8):1672–1678
   PubMed Web of Science ®Google Scholar
• . Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol. 1998;31(5):950–956
   PubMed Web of Science ®Google Scholar
• . Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51( Suppl 3):S368–S376
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Kahn SE, ; GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254–2261
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab. 2005;1(1):22–31
   PubMedGoogle Scholar
• . Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways [Erratum in Circulation. 2008;118(4):e81]. Circulation. 2008;117(18):2340–2350
   PubMed Web of Science ®Google Scholar
• . Chinda K, Chattipakorn S, Chattipakorn N. Cardioprotective effects of incretin during ischaemia-reperfusion. Diab Vasc Dis Res. 2012;9(4):256–269
   PubMed Web of Science ®Google Scholar
• . Fields AV, Patterson B, Karnik AA, Shannon RP. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol. 2009;32(5):236–243
   PubMed Web of Science ®Google Scholar
• . Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther. 2005;19(1):9–11
   PubMed Web of Science ®Google Scholar
• . Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–699
   PubMed Web of Science ®Google Scholar
• . Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408–413
   PubMed Web of Science ®Google Scholar
• . Lønborg J, Vejlstrup N, Kelbæk H, . Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491–1499
   PubMed Web of Science ®Google Scholar
• . Blonde L, Klein EJ, Han J, . Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436–447
   PubMed Web of Science ®Google Scholar
• . Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 2012;8:621–629
   PubMedGoogle Scholar
• . Nauck M, Frid A, Hermansen K, ; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22
   PubMed Web of Science ®Google Scholar
• . Marso SP, Lindsey JB, Stolker JM, . Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8(3):237–240
   PubMed Web of Science ®Google Scholar
• . Monami M, Cremasco F, Lamanna C, . Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764
   PubMedGoogle Scholar
• . National Institutes of Health. Researching Cardiovascular Events With a Weekly Incretin In Diabetes (REWIND). http://clinicaltrials.gov/show/NCT01394952. Updated September 3, 2013. Accesed May 1, 2014
   Google Scholar
• . National Institutes of Health. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. http://www.clinicaltrials.gov/ct2/show/NCT01144338. Updated April 2, 2014. Accesed May 1, 2014
   Google Scholar
• . National Institutes of Health. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER). http://www.clinicaltrials.gov/ct2/show/NCT01179048. Updated March 10, 2014. Accesed May 1, 2014
   Google Scholar
• . National Institutes of Health. Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA). http://clinicaltrials.gov/ct2/show/NCT01147250. Updated October 17, 2013. Accesed May 1, 2014
   Google Scholar
• . Vanderheyden M, Bartunek J, Goethals M, . Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med. 2009;47(3):248–252
   PubMed Web of Science ®Google Scholar
• . Green JB. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. Postgrad Med. 2012;124(4):54–61
   PubMed Web of Science ®Google Scholar
• . Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55(1–3):10–16
   PubMed Web of Science ®Google Scholar
• . Fadini GP, Boscaro E, Albiero M, . The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33(7):1607–1609
   PubMed Web of Science ®Google Scholar
• . Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol. 2013;167(1):87–93
   PubMed Web of Science ®Google Scholar
• . Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195–201
   PubMed Web of Science ®Google Scholar
• . Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–235
   PubMed Web of Science ®Google Scholar
• . Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3
   PubMed Web of Science ®Google Scholar
• . Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6
   PubMed Web of Science ®Google Scholar
• . Mistry GC, Maes AL, Lasseter KC, . Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592–598
   PubMed Web of Science ®Google Scholar
• . Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56(4):728–733
   PubMed Web of Science ®Google Scholar
• . Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516–523
   PubMed Web of Science ®Google Scholar
• . Frederich R, Alexander JH, Fiedorek FT, . A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population [Erratum in Diabetes Obes Metab. 2010;12(9):832]. Diabetes Obes Metab. 2010;12(6):485–494
   PubMed Web of Science ®Google Scholar
• . White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(7):668–673
   PubMed Web of Science ®Google Scholar
• . Williams-Herman D, Engel SS, Round E, . Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7
   PubMed Web of Science ®Google Scholar
• . Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112–120
   PubMed Web of Science ®Google Scholar
• . Scirica BM, Bhatt DL, Braunwald E, ; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326
   PubMed Web of Science ®Google Scholar
• . White WB, Cannon CP, Heller SR, ; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335
   PubMed Web of Science ®Google Scholar
• . Scirica BM, Braunwald E, Bhatt DL. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med. 2014;370(5):483–484
   PubMed Web of Science ®Google Scholar
• . National Institutes of Health. Sitagliptin Cardiovascular Outcome Study (0431–082 AM1) (TECOS). http://clinicaltrials.gov/show/NCT00790205. Accessed May 1, 2014
   Google Scholar
• . National Institutes of Health. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes. http://clinicaltrials.gov/ct2/show/NCT01243424?term=linagliptin&rank=12. Updated April 2, 2014. Accessed May 1, 2014
   Google Scholar
• . National Institutes of Health. CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk. http://clinicaltrials.gov/ct2/show/NCT01897532?term=CARMELINA&rank=1. Updated April 20, 2014. Accessed May 1, 2014
   Google Scholar
• . Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460–3468
   PubMed Web of Science ®Google Scholar
• . Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;(120):S1–S6
   Google Scholar
• . Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Aggarwal N, Polidori D, ; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–1238
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–728
   PubMed Web of Science ®Google Scholar
• . Neal B, Perkovic V, de Zeeuw D, . Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217–223.e211
   PubMed Web of Science ®Google Scholar
• . National Institutes of Health. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). http://clinicaltrials.gov/show/NCT01730534. Updated February 4, 2014. Accessed May 1, 2014
   Google Scholar
• . National Institutes of Health. BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients. http://clinicaltrials.gov/ct2/show/NCT01131676. Updated Apri 30, 2014. Accessed May 1, 2014
   Google Scholar
• . Mary H. Parks; Center for Drug Evaluation and Research. Summary review: Invocana (canagliflozin). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000SumR.pdf. Published March 29, 2013. Accessed May 1, 2014
   Google Scholar
• . US Food and Drug Administration. FDA briefing document: NDA 204042, Invokana (canagliflozin) tablets. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Published January 10, 2013. Accessed May 1, 2014
   Google Scholar
• . US Food and Drug Administration. FDA briefing document: NDA 202293, Dapagliflozin tablets, 5 and 10 mg. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugsEndocrinologicandMetabolicDrugs/AdvisoryCommittee/ucm262994.pdf. Published July 19, 2011. Accessed May 1, 2014
   Google Scholar
• . Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab. 2012;14(1):1–4
   PubMed Web of Science ®Google Scholar
• . ; BARI 2D Study GroupFrye RL, August P, Brooks MM, A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–2515
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA briefing document: NDA 203313 and NDA 203314, insulin Degludec and insulin Degludec/Aspart. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf. Published November 8, 2012. Accessed May 1, 2014
   Google Scholar
• . Rajpathak SN, Aggarwal V, Hu FB. Multifactorial intervention to reduce cardiovascular events in type 2 diabetes. Curr Diab Rep. 2010;10(1):16–23
   PubMed Web of Science ®Google Scholar
• . Al-Delaimy WK, Manson JE, Solomon CG, . Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med. 2002;162(3):273–279
   PubMedGoogle Scholar
• . Turner RC, Millns H, Neil HA, . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823–828
   PubMed Web of Science ®Google Scholar
• . Clair C, Rigotti NA, Porneala B, . Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309(10):1014–1021
   PubMed Web of Science ®Google Scholar
• . Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010 [Erratum in N Engl J Med. 2013;369(6):587]. N Engl J Med. 2013;368(17):1613–1624
   PubMed Web of Science ®Google Scholar
• . Curb JD, Pressel SL, Cutler JA, . Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group [Erratum in JAMA. 1997;277(17):1356]. JAMA. 1996;276(23):1886–1892
   PubMed Web of Science ®Google Scholar
• . Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840
   PubMed Web of Science ®Google Scholar
• . Turnbull F, Neal B, Algert C, ; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410–1419
   PubMedGoogle Scholar
• . Hansson L, Zanchetti A, Carruthers SG, . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–1762
   PubMed Web of Science ®Google Scholar
• . Tuomilehto J, Rastenyte D, Birkenhäger WH, . Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340(9):677–684
   PubMed Web of Science ®Google Scholar
• . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [Erratum in BMJ. 1999;318(7175):29]. BMJ. 1998;317(7160):703–713
   PubMed Web of Science ®Google Scholar
• . ; ACCORD Study GroupCushman WC, Evans GW, Byington RP, Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585
   PubMed Web of Science ®Google Scholar
• . Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003;5( Suppl 1):S19–S27
   PubMed Web of Science ®Google Scholar
• . Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs. 2007;67( Suppl 1):43–54
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, ; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–2016
   PubMed Web of Science ®Google Scholar
• . de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72(18):2365–2373
   PubMed Web of Science ®Google Scholar
• . Stone NJ, Robinson J, Lichtenstein AH, . 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 7, 2013]. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.11.002
   Google Scholar
• . Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279
   PubMed Web of Science ®Google Scholar
• . Farkouh ME, Boden WE, Bittner V, . Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013;61(15):1607–1615
   PubMed Web of Science ®Google Scholar
• . Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
   PubMed Web of Science ®Google Scholar
• . Griffin SJ, Borch-Johnsen K, Davies MJ, . Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial [Erratum in Lancet. 2012;379(9818):804]. Lancet. 2011;378(9786):156–167
   PubMed Web of Science ®Google Scholar
• . Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010;7(4):260–273
   PubMed Web of Science ®Google Scholar
• . Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992;268(10):1292–1300
   PubMed Web of Science ®Google Scholar
• . Belch J, MacCuish A, Campbell I, ; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840
   PubMed Web of Science ®Google Scholar
• . ; Antithrombotic Trialists' (ATT) CollaborationBaigent C, Blackwell L, Collins R, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860
   PubMed Web of Science ®Google Scholar
• . Ogawa H, Nakayama M, Morimoto T, ; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial [Erratum in JAMA. 2009;301(18):1882, and JAMA. 2012;308(18):1861]. JAMA. 2008;300(18):2134–2141
   PubMed Web of Science ®Google Scholar
• . Franco M, Bilal U, Orduñez P, . Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980–2010: repeated cross sectional surveys and ecological comparison of secular trends. BMJ. 2013;346:f1515
   PubMed Web of Science ®Google Scholar
• . Barengo NC, Katoh S, Moltchanov V, Tajima N, Tuomilehto J. The diabetes-cardiovascular risk paradox: results from a Finnish population-based prospective study. Eur Heart J. 2008;29(15):1889–1895
   PubMed Web of Science ®Google Scholar